GSK is stepping up its push to get vaccines in arms. With adult vaccination rates now rebounding from a pandemic-era slump, the Big Pharma is doubling its financial support for an uptake initiative ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...